Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository

P. C. Mathias, Nathaniel Hendrix, W. J. Wang, K. Keyloun, M. Khelifi, P. Tarczy-Hornoch, B. Devine*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The extent to which pharmacogenomic-guided medication use has been adopted in various health systems is unclear. To assess the uptake of pharmacogenomic-guided medication use, we determined its frequency across our health system, which does not have a structured testing program. Using a multisite clinical data repository, we identified adult patients' first prescribed medications between January 2011 and December 2013 and investigated the frequency of germline and somatic pharmacogenomic testing, by the Pharmacogenomics Knowledgebase level of the US Food and Drug Administration label information. There were 268,262 medication orders for drugs with germline pharmacogenomic testing information in their drug labels. Pharmacogenomic testing was detected for 1.5% (129/8,718) of medication orders with recommended or required testing. Of the 3,817 medication orders associated with somatic pharmacogenomic testing information in their drug labels, 20% (372/1,819) of required tests were detected. The low rates of detectable pharmacogenomic testing suggest that structured testing programs are required to achieve the success of precision medicine.

Original languageEnglish
Pages (from-to)340-348
Number of pages9
JournalClinical Pharmacology and Therapeutics
Issue number2
Publication statusPublished - 1 Aug 2017
Externally publishedYes

Cite this